Zenas BioPharma, Inc. — Form SCHEDULE 13D/A
Filed August 19, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 24/100
What the filing says
Enavate Sciences GP, LLC filed an amended Schedule 13D/A regarding its beneficial ownership position in Zenas BioPharma, Inc. (public market cap ~$259.3M). The filing document itself contains no substantive disclosure of specific share counts, ownership percentages, transaction amounts, dates of changes, or what material facts were amended — only header/administrative metadata is visible in this SEC filing text.
Why this rating
Amendment to existing 13D without disclosed material changes; lack of concrete new information prevents assessment of actual ownership shift impact.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.